Lnc-ing epicardium-derived cells to cardiac remodelling: lncRNA-TARID as a novel antifibrotic option

Xuekun Wu; Francesca Vacante; Joseph C. Wu

doi:10.1093/eurheartj/ehad058

March 17, 2023European Heart JournalOpen Access

Lnc-ing epicardium-derived cells to cardiac remodelling: lncRNA-TARID as a novel antifibrotic option

View Full Paper

Ask AI

Bookmark

Share

Key result

Intrapericardial lncRNA-TARID therapy mitigates myocardial fibrosis, serving as a novel antifibrotic option for cardiac remodeling.

Why the study?

Does intrapericardial lncRNA-TARID therapy mitigate myocardial fibrosis?

Structured PICO

Does intrapericardial lncRNA-TARID therapy mitigate myocardial fibrosis?

P

Population

Preclinical model of myocardial fibrosis (implied)

I

Intervention

Intrapericardial lncRNA-TARID therapy

O

Outcome

Myocardial fibrosissurrogate

Intrapericardial lncRNA-TARID therapy represents a potential novel antifibrotic option for mitigating myocardial fibrosis.

Implication

Hypothesis-generating for antifibrotic therapy; leaves open translation to human myocardial fibrosis.

Abstract

Intrapericardial lncRNA-TARID therapy mitigates myocardial fibrosis. The figure was designed by using BioRender.com.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2023) studied this question. Intrapericardial lncRNA-TARID therapy mitigates myocardial fibrosis, serving as a novel antifibrotic option for cardiac remodeling.

synapsesocial.com/papers/6a988465f913bc050cedcacf https://doi.org/10.1093/eurheartj/ehad058

View Full Paper

Ask AI

Bookmark

Share

Lnc-ing epicardium-derived cells to cardiac remodelling: lncRNA-TARID as a novel antifibrotic option

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Lnc-ing epicardium-derived cells to cardiac remodelling: lncRNA-TARID as a novel antifibrotic option

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading